Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease Lineage (NYSE: LCTX) launched COR1, a new internally developed corneal endothelial cell (CEnC) therapy program in preclinical development for corneal endothelial disease, including Fuchs Endothelial Corneal Dystrophy and bullous keratopathy. Lineage reports manufacturing of off-the-shelf CEnCs that meet initial internal identity, morphological, and functional criteria using its AlloSCOPE platform.The company cites donor shortages (one donor per 70 diseased eyes) and aims to leverage AlloSCOPE and a proprietary pluripotent cell line to scale production and potentially reduce costs via its AlloSCOPE “5D” process.

#LCTX Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease

www.stocktitan.net/news/LCTX/lineage-launch...

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update Continued progress with the OpRegen cell therapy program, including achievement of the first of the $620 million of milestone payments available under our collaboration with Roche and Genentech; a milestone rooted in our manufacturing expertise and reflecting years of investment to optimize our in-house production processes. Solidified our position...

#LCTX Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/LCTX/lineage-cell-t...

Leading Indicators, Wednesday November 12, 2025 – Crystal Equity Research

Small-cap stocks wtih improving money flow, Wed Nov 12th - #LCTX #VMAR #SOND #PAL #MLTX #PLTX #FMBH #EVER #DIPS #CEPO #SPRU #PBT #OWLT #NMM #IMAX #GFR - More: crystalequityresearch.com/leading-indi... - #smallcap

#LCTX Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/LCTX/lineage-cell-t...

Leading Indicators, Thursday September 25, 2025 – Crystal Equity Research

Small-cap stocks with improving money flow, Thu Sept 25th - #SLI #LCTX #XMTR #VECO #TLS #SEPN #PPSI #ONDS #MASS #IRD #EVAX #IBO #DXLG #CLRB #BTOC #AENT #VOC #SBR #OWLT #INVX #DQ #AMBC - More: crystalequityresearch.com/leading-indi... - #smallcap

$12M Hearing Loss Breakthrough: Lineage Cell Partners with Global Leader to Develop Novel Cell Therapy Biotech firm Lineage partners with William Demant Invest on ReSonance cell therapy for hearing loss. 3-year collaboration includes $12M funding to advance preclinical development.

#LCTX Lineage Announces Research Collaboration With William Demant Invest to Develop ReSonance™ (ANP1) for Hearing Loss

www.stocktitan.net/news/LCTX/lineage-announ...

🔍 FeetrAI Alert: #LCTX is in a consolidation phase at $0.98 with bearish signals! RSI near oversold, MACD negative, and price below key SMAs. Consider a SHORT at $0.98, targeting $0.95 & $0.92. Stop loss at $1.02. Stay cautious, watch for biotech news! 📉 #StockAnalysis

Breakthrough: Novel Stem Cell Treatment OPC1 Reaches Major Milestone in Chronic Spinal Cord Injury Study Lineage's innovative OPC1 cell therapy achieves historic first treatment of chronic spinal cord injury patient using new delivery system. Learn trial details.

#LCTX Lineage Announces Dosing of First Patient in New Clinical Study of OPC1 for Subacute and Chronic Spinal Cord Injury

www.stocktitan.net/news/LCTX/lineage-announ...

🚨 FeetrAI Alert: #LCTX is on our radar! Trading at $1.029, it's facing resistance with a 10-day SMA of $1.051 and a 20-day EMA of $1.023. RSI hints at bearish momentum, while low volume signals caution. Consider SHORT at $1.03, targeting $1.00 & $0.95. Stop loss: $1.06. 📉 #Biotech #Stocks

🚀 Exciting times for #LCTX! Trading at $1.08, with a potential upward momentum as 10-day SMA hits $1.05 and 20-day EMA at $1.02. 📈 Consider a long position at $1.06, targeting $1.12 & $1.15. Stay cautious of market volatility, but optimism is in the air! #FeetrAI

🚨 FeetrAI Alert: #LCTX is in the spotlight! Trading at $1.04 with low volume, it's showing mixed signals. RSI is neutral, but MACD hints bearish. Consider a short at $1.05, targeting $1.02 & $0.98. Stop loss at $1.08. Watch for stem cell therapy news! 📉 #Stocks #FeetrAI

🚀 Exciting times for #LCTX! Trading at $1.094, Lineage Cell Therapeutics shows bullish momentum with a 10-day SMA above the 20 & 30-day SMAs and a positive MACD. Consider a long position targeting $1.15-$1.18, but stay alert to market shifts! 📈 #FeetrAI #StockWatch

🚀 Exciting times for #LCTX! With strong upward momentum from recent clinical trial wins and strategic partnerships, this biotech gem is on the move. 📈 Technicals show a bullish trend, but watch for consolidation. Targeting $1.20 & $1.25 with a stop at $1.05. Stay tuned! #Biotech #Stocks #FeetrAI

🚀 Exciting times for #LCTX! Positive OpRegen trial results are fueling bullish momentum. 📈 RSI hints at overbought, but MACD suggests consolidation before more gains. Enter around $1.17, target $1.25-$1.30, stop loss at $1.10. Stay sharp on biotech risks! #FeetrAI

🚀 Exciting times for #LCTX! Positive clinical trials and a big pharma partnership are fueling an uptrend. With bullish technicals and strong sector vibes, it's poised for growth. Enter at $1.03, target $1.10 & $1.15. Stop loss at $0.98. Stay sharp, investors! 📈 #FeetrAI

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#CPB, #SXC, #UPXI, #FIVN, #LCTX

#OptionFlow #OptionsTrading #Trading

🚀 Exciting times for #LCTX! Trading at $1.03, Lineage Cell Therapeutics is riding high on positive OpRegen trial results. With bullish indicators and room to grow, consider a long position targeting $1.10-$1.15. Stay sharp, as volatility adds spice! #BiotechBoom

🚀 Exciting times for #LCTX! Trading at $1.03, it's riding a bullish wave with strong SMA & EMA signals. RSI in the low 60s shows healthy buying pressure. With OpRegen buzz and buyout rumors, consider a long position. Targets: $1.10 & $1.15. Stop loss: $0.95. 📈 #BiotechBoom

🚀 Exciting times for #LCTX! Positive trial results & strategic partnerships hint at upward momentum. With a bullish trend and sector strength, consider a long position at $1.02, targeting $1.10 & $1.15. Caution: low volume today may mean volatility. #Biotech #FeetrAI

🚀 Exciting times for #LCTX! With a promising setup and recent positive trial results, this biotech gem is catching eyes. Enter around $0.99, target $1.05 & $1.10. Stop loss at $0.95. Moderate bullish momentum with market optimism. Stay tuned for potential buyout buzz! 📈 #Biotech #Stocks

🚀 Exciting times for #LCTX! Trading at $0.9996, Lineage Cell Therapeutics is riding high on positive OpRegen trial results. With bullish SMA & EMA trends, consider a LONG position targeting $1.05-$1.10. But watch out for overbought RSI & market volatility! 📈 #FeetrAI

🚀 Exciting times for #LCTX! Bullish momentum from positive trial results and acquisition buzz! 📈 Trading above key averages with RSI at 65. Watch for potential consolidation, but a long position could target $1.10-$1.15. Stay alert for news! #Biotech #Stocks #FeetrAI

🚀 Exciting times for #LCTX! Positive Phase 1/2a results for OpRegen are driving momentum, with strong technicals signaling a bullish trend. Consider a long position around $0.995, targeting $1.05 & $1.10. Watch for acquisition buzz! 📈 #FeetrAI #StockMarket #Biotech

🚀 Exciting times for #LCTX! With positive OpRegen trial results and buyout buzz, this stock is on the move. Trading at $0.93, it's nearing overbought territory but bullish sentiment is strong. Targeting $1.00-$1.10 with a stop at $0.88. Stay sharp, traders! 📈 #FeetrAI

🚀 Exciting times for #LCTX! Bullish momentum fueled by positive trial results & partnership buzz. With the 10-day SMA at $0.95, there's room to grow from $0.91. MACD is positive, RSI neutral. Consider a long position targeting $0.95-$1.00, but stay alert! 📈 #FeetrAI

🚀 Exciting times for #LCTX! Positive Phase 1/2a trial results for OpRegen are driving momentum. With a bullish trend and strong volume, consider a long position at $0.92, targeting $0.95 & $1.00. Stop loss at $0.88. Dive in for potential gains! 📈 #FeetrAI #Stocks

🚀 Exciting times for #LCTX! Positive trial results & a new pharma partnership are sparking investor interest. With mixed technicals, consider a long position at $0.91, targeting $0.95 & $1.00. Stay cautious with volatility & market trends. 📈 #FeetrAI #StockWatch

🚀 Exciting times for #LCTX! Trading at $0.9352, it's showing bullish momentum with positive MACD and upward SMAs. Recent trial results and acquisition buzz add fuel! Consider a LONG position targeting $1.00-$1.05, but watch for market volatility. #Stocks #FeetrAI

🚀 Exciting times for #LCTX! Bullish momentum fueled by positive trial results & partnership rumors. 📈 Technicals show strong upward trend with room to grow. Consider a long position at $0.93, targeting $1.05 & $1.15. Stop loss at $0.88. Stay tuned for partnership news! 💡 #Stocks #Biotech

🚀 Exciting times for #LCTX! Bullish momentum is fueled by positive trial results in stem cell therapy, pushing prices above key moving averages. With a strong MACD and market sentiment, we're eyeing targets of $1.15 & $1.20. 📈 Dive in, but stay sharp! #Biotech #FeetrAI